Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36:310–8.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769–70.

Article  PubMed  Google Scholar 

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116:2857–8.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32:1631–42.

Article  PubMed  PubMed Central  Google Scholar 

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv. 2022;6:1855–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kröger N. Reduced intensity vs. standard conditioning followed by allogeneic stem cell transplantation for patients with MDS or secondary AML: a prospective, randomized phase III study of the chronic malignancies working party of the EBMT (RICMAC-Trial) [Abstract ASH 2014]. Blood. 2014;124:320.

Article  Google Scholar 

Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015; https://doi.org/10.1038/leu.2015.233.

McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019;104:659–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124:1183–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robin M, Francois S, Huynh A, Cassinat B, Bay J-O, Cornillon J, et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by goelams-FIM in collaboration with the Sfgmtc. Blood. 2013;122:306.

Article  Google Scholar 

McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, et al. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:2167–71.

Article  PubMed  Google Scholar 

Deeg HJ, Salit RB, Monahan T, Schoch G, McFarland C, Scott BL, et al. Early mixed lymphoid donor/host chimerism is associated with improved transplant outcome in patients with primary or secondary myelofibrosis. Biol Blood Marrow Transplant. 2020;26:2197–203.

Article  PubMed  PubMed Central  Google Scholar 

Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, et al. Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2016;22:1206–11.

Article  PubMed  Google Scholar 

Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, et al. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2019;54:204–11.

Article  CAS  PubMed  Google Scholar 

Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, et al. Optimizing the conditioning regimen for hematopoietic cell transplant in myelofibrosis: long-term results of a prospective phase II clinical trial. Biol Blood Marrow Transplant. 2020;26:1439–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patriarca F, Masciulli A, Bacigalupo A, Bregante S, Pavoni C, Finazzi MC, et al. Busulfan- or thiotepa-based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO group. Biol Blood Marrow Transplant. 2019;25:932–40.

Article  CAS  PubMed  Google Scholar 

Battipaglia G, Mauff K, Wendel L, Angelucci E, Mohty M, Arcese W, et al. Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2021;56:1593–602.

Article  CAS  PubMed  Google Scholar 

Chiusolo P, Bregante S, Giammarco S, Lamparelli T, Casarino L, Dominietto A, et al. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: the role of the conditioning regimen. Am J Hematol. 2021;96:234–40.

Article  CAS  PubMed  Google Scholar 

Shouval R, Vega Y, Fein JA, Danylesko I, Shem Tov N, Yerushalmi R, et al. Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis. Bone Marrow Transplant. 2020;55:147–56.

Article  CAS  PubMed  Google Scholar 

Claudiani S, Marktel S, Piemontese S, Assanelli A, Lupo-Stanghellini MT, Carrabba M, et al. Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Hematol Oncol. 2016;34:154–60.

Article  CAS  PubMed  Google Scholar 

Shimoni A, Shem-Tov N, Volchek Y, Danylesko I, Yerushalmi R, Nagler A. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Bone Marrow Transplant. 2012;47:1274–82.

Article  CAS  PubMed  Google Scholar 

Sakellari I, Mallouri D, Gavriilaki E, Batsis I, Kaliou M, Constantinou V, et al. Survival advantage and comparable toxicity in reduced-toxicity treosulfan-based versus reduced-intensity busulfan-based conditioning regimen in myelodysplastic syndrome and acute myeloid leukemia patients after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23:445–51.

Article  CAS  PubMed  Google Scholar 

Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2011;17:341–50.

Article  CAS  PubMed  Google Scholar 

Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, et al. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol. 2010;28:3344–51.

Article  CAS  PubMed  Google Scholar 

Atagunduz IK, Klyuchnikov E, Wolschke C, Janson D, Heidenreich S, Christopeit M, et al. Treosulfan-based conditioning regimen for second allograft in patients with myelofibrosis. Cancers. 2020;12:E3098.

Article  Google Scholar 

Shimoni A, Robin M, Iacobelli S, Beelen D, Mufti GJ, Ciceri F, et al. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. Br J Haematol. 2021;195:417–28.

Article  CAS  PubMed  Google Scholar 

Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7:e28–e39.

Article  PubMed  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.

Article  PubMed  PubMed Central  Google Scholar 

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367–9.

Article  PubMed  PubMed Central  Google Scholar 

Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108:1497–503.

Article  CAS  PubMed  Google Scholar 

Iacobelli S.EBMT statistical committeeSuggestions on the use of statistical methodologies in studies of the European Group For Blood And Marrow Transplantation. Bone Marrow Transplant. 2013;48:S1–37.

Article  PubMed  Google Scholar 

Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55:1114–25.

Article  CAS  PubMed  Google Scholar 

Tamari R, McLornan DP, Ahn KW, Estrada-Merly N, Hernández-Boluda JC, Giralt S, et al. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis. Blood Adv. 2023;7:3993–4002.

Article  CAS  PubMed  PubMed Central  Google Scholar